Hemotune Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$17.4M
- Investors
-
17
Hemotune General Information
Description
Developer of a therapeutic blood purification platform designed to develop blood purification technology. The company's platform offers treatments based on magnetic beads that allow selective and efficient removal of large biomolecules directly from blood and focuses on the immunological aspects of sepsis that tackle multiple disease pathways, enabling patients to get the required treatment for blood-related diseases.
Contact Information
Website
www.hemotune.comCorporate Office
- Wagistrasse 27
- Schlieren
- 8952 Zurich
- Switzerland
Corporate Office
- Wagistrasse 27
- Schlieren
- 8952 Zurich
- Switzerland
Hemotune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Later Stage VC (Series B2) | 01-Dec-2025 | $17.4M | Completed | Startup | ||
| 14. Later Stage VC (Series B1) | 26-Apr-2022 | Completed | Startup | |||
| 13. Early Stage VC (Series A) | 12-Aug-2020 | Completed | Startup | |||
| 12. Grant | 09-Jul-2020 | Completed | Startup | |||
| 11. Grant | 07-Feb-2020 | Completed | Startup | |||
| 10. Grant | 23-Oct-2018 | Completed | Startup | |||
| 9. Accelerator/Incubator | 05-Jul-2017 | Completed | Startup | |||
| 8. Accelerator/Incubator | 01-May-2017 | Completed | Startup | |||
| 7. Grant | 01-May-2017 | $440K | $446K | Completed | Startup | |
| 6. Grant | 28-Mar-2017 | $19.9K | $446K | Completed | Startup |
Hemotune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 53,960 | $1.243867 | $74.92 | $74.92 | 1x | $74.92 | 15.53% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Hemotune Comparisons
Industry
Financing
Details
Hemotune Competitors (8)
One of Hemotune’s 8 competitors is Immunicom, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immunicom | Venture Capital-Backed | San Diego, CA | ||||
| NaNotics | Venture Capital-Backed | Mill Valley, CA | ||||
| MediSieve | Venture Capital-Backed | London, United Kingdom | ||||
| ExThera Medical | Venture Capital-Backed | Martinez, CA | ||||
| Spectral Medical | Corporation | Toronto, Canada |
Hemotune Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hemotune Patents
Hemotune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025214591-A1 | Conjugates of magnetic particles and viral structures and their use in medical applications | Pending | 10-Apr-2024 | ||
| WO-2025215035-A1 | Conjugates of magnetic particles and viral structures and their use in medical applications | Pending | 10-Apr-2024 | ||
| EP-4801571-A1 | Synthesis and application of magnetic particle conjugates for the extracorporeal removal of antibodies targeting viral vectors to facilitate gene therapy | Pending | 10-Apr-2024 | ||
| WO-2025214592-A1 | Synthesis and application of magnetic particle conjugates for the extracorporeal removal of antibodies targeting viral vectors to facilitate gene therapy | Pending | 10-Apr-2024 | ||
| WO-2025215034-A1 | Synthesis and application of magnetic particle conjugates for the extracorporeal removal of antibodies targeting viral vectors to facilitate gene therapy | Pending | 10-Apr-2024 | A61K47/6923 |
Hemotune Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hemotune Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Belmondo Family Office | Family Office | Minority | ||
| EFI Lake Geneva Ventures | Venture Capital | Minority | ||
| Hemex (Healthcare Services) | VC-Backed Company | Minority | ||
| VP Venture Partners | Venture Capital | Minority | ||
| GC Biopharma | Corporation | Minority |
Hemotune FAQs
-
When was Hemotune founded?
Hemotune was founded in 2016.
-
Where is Hemotune headquartered?
Hemotune is headquartered in Zurich, Switzerland.
-
What is the size of Hemotune?
Hemotune has 33 total employees.
-
What industry is Hemotune in?
Hemotune’s primary industry is Therapeutic Devices.
-
Is Hemotune a private or public company?
Hemotune is a Private company.
-
What is the current valuation of Hemotune?
The current valuation of Hemotune is .
-
What is Hemotune’s current revenue?
The current revenue for Hemotune is .
-
How much funding has Hemotune raised over time?
Hemotune has raised $35.9M.
-
Who are Hemotune’s investors?
Belmondo Family Office, EFI Lake Geneva Ventures, Hemex (Healthcare Services), VP Venture Partners, and GC Biopharma are 5 of 17 investors who have invested in Hemotune.
-
Who are Hemotune’s competitors?
Immunicom, NaNotics, MediSieve, ExThera Medical, and Spectral Medical are some of the 8 competitors of Hemotune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
